IGMS IGM Biosciences
- 10.120
- +0.780+8.35%
IGM Biosciences News
Wedbush: Reiterates IGM Biosciences (IGMS.US) rating and adjusted from superior to superior market rating, with a target price of $20.00.
Wedbush: Reiterates IGM Biosciences (IGMS.US) rating and adjusted from superior to superior market rating, with a target price of $20.00.
Wedbush Reiterates Outperform on IGM Biosciences, Maintains $20 Price Target
Wedbush analyst Robert Driscoll reiterates IGM Biosciences (NASDAQ:IGMS) with a Outperform and maintains $20 price target.
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), IGM Biosciences (IGMS) and Elanco Animal Health (ELAN)
RBC Cuts Price Target on IGM Biosciences to $20 From $21, Keeps Outperform, Speculative Risk
IGM Biosciences (IGMS) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $12 to $48.
IGM Biosciences Q1 EPS $(0.83), Inline, Sales $497.00K Miss $760.00K Estimate
IGM Biosciences (NASDAQ:IGMS) reported quarterly losses of $(0.83) per share which met the analyst consensus estimate. This is a 37.59 percent increase over losses of $(1.33) per share from the same p
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates
Earnings Flash (IGMS) IGM BIOSCIENCES Posts Q1 Collaboration Revenue $497,000
04:42 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (IGMS) IGM BIOSCIENCES Posts Q1 Collaboration Revenue $497,000
IGM Biosciences | 10-Q: Quarterly report
Press Release: IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update - Enrollment target exceeded in aplitabart randomized colorectal cancer clinical trial - - Enrollment com
IGM Biosciences 1Q Loss $49.8M >IGMS
IGM Biosciences 1Q Loss $49.8M >IGMS
IGM Biosciences 1Q Loss/Shr 83c >IGMS
IGM Biosciences 1Q Loss/Shr 83c >IGMS
IGM Biosciences to Present at the 2024 RBCCM Global Healthcare Conference
MOUNTAIN VIEW, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management
Stifel Nicolaus Sticks to Its Buy Rating for IGM Biosciences (IGMS)
IGM Biosciences Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
IGM Biosciences Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
HC Wainwright & Co. Reiterates Neutral on IGM Biosciences, Maintains $12 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates IGM Biosciences with a Neutral and maintains $12 price target.
Analysts' Opinions Are Mixed on These Healthcare Stocks: IGM Biosciences (IGMS) and Argenx Se (ARGX)
Why IGM Biosciences Is Rising In Pre-market?
IGM Biosciences Announces Worldwide Collaboration Agreement With Sanofi To Create And Develop IgM Agonist Antibodies Will Focus Exclusively On Immunology/Inflammation Targets
IGM Biosciences Announces Worldwide Collaboration Agreement With Sanofi To Create And Develop IgM Agonist Antibodies Will Focus Exclusively On Immunology/Inflammation Targets
IGM Biosciences Announces Refocusing of Sanofi Collaboration
MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that the
IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum
MOUNTAIN VIEW, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announ
Analysis
Price Target
No Data
